Correlation Between Krystal Biotech and Arrowhead Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Krystal Biotech and Arrowhead Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Krystal Biotech and Arrowhead Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Krystal Biotech and Arrowhead Pharmaceuticals, you can compare the effects of market volatilities on Krystal Biotech and Arrowhead Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Krystal Biotech with a short position of Arrowhead Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Krystal Biotech and Arrowhead Pharmaceuticals.

Diversification Opportunities for Krystal Biotech and Arrowhead Pharmaceuticals

0.73
  Correlation Coefficient

Poor diversification

The 3 months correlation between Krystal and Arrowhead is 0.73. Overlapping area represents the amount of risk that can be diversified away by holding Krystal Biotech and Arrowhead Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Arrowhead Pharmaceuticals and Krystal Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Krystal Biotech are associated (or correlated) with Arrowhead Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Arrowhead Pharmaceuticals has no effect on the direction of Krystal Biotech i.e., Krystal Biotech and Arrowhead Pharmaceuticals go up and down completely randomly.

Pair Corralation between Krystal Biotech and Arrowhead Pharmaceuticals

Given the investment horizon of 90 days Krystal Biotech is expected to generate 0.92 times more return on investment than Arrowhead Pharmaceuticals. However, Krystal Biotech is 1.09 times less risky than Arrowhead Pharmaceuticals. It trades about 0.07 of its potential returns per unit of risk. Arrowhead Pharmaceuticals is currently generating about 0.0 per unit of risk. If you would invest  11,637  in Krystal Biotech on August 25, 2024 and sell it today you would earn a total of  7,403  from holding Krystal Biotech or generate 63.62% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Krystal Biotech  vs.  Arrowhead Pharmaceuticals

 Performance 
       Timeline  
Krystal Biotech 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Krystal Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Krystal Biotech is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.
Arrowhead Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Arrowhead Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Krystal Biotech and Arrowhead Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Krystal Biotech and Arrowhead Pharmaceuticals

The main advantage of trading using opposite Krystal Biotech and Arrowhead Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Krystal Biotech position performs unexpectedly, Arrowhead Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will offset losses from the drop in Arrowhead Pharmaceuticals' long position.
The idea behind Krystal Biotech and Arrowhead Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Complementary Tools

Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities